Abstract：
:The product pipeline for diseases that disproportionately affect the developing world has considerably expanded over the last decade. Indeed, there are about 134 products for these diseases in the pipeline, including vaccines, drugs, diagnostics, microbicides, and vector control tools, and dozens of these products are currently being evaluated in human trials in developing countries where the disease of interest exists. While these efforts are underway, the need to identify regulatory pathways for licensing these new products is becoming obvious to many manufacturers. In many developing countries, where the need of these products is greatest, the national regulatory authorities often lack the resources and regulatory capacity to review the registration dossiers to approve the use of new products. Given this challenge, new regulatory models are urgently needed to offset product registration. In this paper, we propose how regional regulatory frameworks established by regional harmonization initiatives can be used to set up an integrated regional licensing system, a system that will provide for a single product dossier application and a single review, leading to a single approval that will grant access to all the markets in the region. The proposed model aims at complementing the ongoing regional regulatory harmonization efforts by pooling the activities of different national expertise groups so as to make the best use of the available skills at a reduced cost. By sharing the various regulatory tasks in an integrated manner, the total process will be accelerated and will facilitate product registration in the region.
journal_name
Ther Innov Regul Scijournal_title
Therapeutic innovation & regulatory scienceauthors
Saidu Y,De Angelis D,Aiolli S,Stefano G,Georges AMdoi
10.1177/2168479013478952subject
Has Abstractpub_date
2013-05-01 00:00:00pages
327-335issue
3eissn
2168-4790issn
2168-4804journal_volume
47pub_type
杂志文章abstract：:Using a measure of agreement that does not distinguish the "positive" outcome from the "negative" outcome can be sometimes misleading in assessing resemblance. To alleviate this concern, some new indices, including the "positive" and "negative" conditional synchrony measures (CSM) (or the conditional discordant measur...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1007/s43441-019-00074-6
更新日期：2020-03-01 00:00:00
abstract：BACKGROUND:Medical information (MI) departments across pharmaceutical companies respond to medical inquiries about a company's products to healthcare providers, payors, patients, and caregivers. Responses provided are constructed to be relevant, accurate, scientifically balanced and delivered in a timely manner. Benchm...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1007/s43441-020-00137-z
更新日期：2020-11-01 00:00:00
abstract：:The regulatory agencies all over the world have defined the pathway and regulations for the approval of simple small-molecule generics. In addition, the agencies are striving to form perspicuous regulatory frameworks for the approval of biosimilars. In this view, there are no defined regulations for the approval of co...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章,评审
doi：10.1007/s43441-020-00114-6
更新日期：2020-09-01 00:00:00
abstract：:The Tufts Center for the Study of Drug Development and Medidata Solutions Inc analyzed data from 9737 protocols and 130,601 investigative site contracts associated with these protocols to derive updated benchmarks characterizing protocol complexity. The results of the study indicate that protocol design complexity con...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1177/2168479017713039
更新日期：2018-01-01 00:00:00
abstract：:Expanded access is a regulatory mechanism by which an investigational drug can be made available outside of a clinical trial to treat patients with serious or life-threatening conditions for which there are no satisfactory treatment options. An expanded access program (EAP) is the formal plan under which preapproval a...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1177/2168479015578154
更新日期：2015-05-01 00:00:00
abstract：:After nearly a decade of discussion, analysis, and development, the Medicines Adaptive Pathways to Patients (MAPPs) initiative is beginning to see acceptance from regulators, industry, patients, and payers, with the first live pilot project initiated under the guidance of the European Medicines Agency in 2014. Althoug...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1177/2168479015618697
更新日期：2016-05-01 00:00:00
abstract：BACKGROUND:Timely access to new medicines may be addressed through strengthening of registration efficiencies and timelines by establishing and refining value-added registration processes, resources, and systems. The aims of this study were to evaluate the timelines of the milestones of the South African review process...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1007/s43441-019-00013-5
更新日期：2020-07-01 00:00:00
abstract：:The U.S. and Japan have preapproval access systems for patients who have exhausted approved treatment options. We compare the systems of both countries and discuss some ethical concerns surrounding non-trial access to investigational drugs. Notable points of comparison of the two countries' systems include cost of non...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1007/s43441-020-00228-x
更新日期：2020-10-23 00:00:00
abstract：BACKGROUND:The pace of innovation, the creative engine of the pharmaceutical industry, has been variably described as stagnant, stable, or accelerating depending on the metric used for assessment or the quality of evidence. If the predominant perception holds that the speed of innovation is sluggish, pressure for chang...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1007/s43441-020-00210-7
更新日期：2020-08-31 00:00:00
abstract：BACKGROUND:According to 21 Code of Federal Regulation (CFR) Part 211, Over-the-Counter (OTC) drug manufacturers must establish and follow current good manufacturing practices (cGMP) to produce quality products while meeting regulatory standards. The warning letters issued by the U.S. Food and Drug Administration (FDA) ...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1007/s43441-020-00231-2
更新日期：2020-10-23 00:00:00
abstract：BACKGROUND:Pediatric regulations enacted in both Europe and the USA have disrupted the pharmaceutical industry, challenging business and drug development processes, and organizational structures. Over the last decade, with science and innovation evolving, industry has moved from a reactive to a proactive mode, investin...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1007/s43441-020-00116-4
更新日期：2020-09-01 00:00:00
abstract：BACKGROUND:The coherence between the relationship of QTc and drug plasma concentration (this relationship is measured through the slope) and ICH E14 findings based on hundreds of QT study reports was studied. RESULTS:Based on ICH E14 analysis, our findings indicate that if the slope was not positive, in most cases (86...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1177/2168479014563549
更新日期：2015-05-01 00:00:00
abstract：:Efficient use of limited pharmaceutical product development resources requires integrating multiple attributes, such as efficacy, safety, pharmacology, and so on, to decide at any stage whether the development of a product should proceed aggressively or slowly or be terminated. The decision process proceeds most effec...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1177/2168479014558273
更新日期：2015-03-01 00:00:00
abstract：:Probability of success in phase II dominates the drug development cost calculus, with phase I/II as the critical juncture for proof of concept. Failure to address fundamental pharmacologic questions in early development is alarmingly frequent and a strong predictor of failure. Safety, manufacture, formulation, and com...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1177/2168479014526600
更新日期：2014-09-01 00:00:00
abstract：:In a global environment where health care costs are soaring, R&D efforts are flatlining. Meanwhile, payers are demanding more value for their money. In this environment, the traditional siloed drug development model is not sustainable. Yet innovations such as adaptive trial designs, real-world data collection, precisi...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1177/2168479018814224
更新日期：2019-05-01 00:00:00
abstract：BACKGROUND:The US Food and Drug Administration (FDA) put out a call for comments on new draft guidance for industry "Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA." This call for comments elicited 7 submissions from various organization...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章,评审
doi：10.1177/2168479018775659
更新日期：2019-03-01 00:00:00
abstract：BACKGROUND:Predictions of drug sales play an important role in setting drug prices in Japan, where drug prices are highly regulated. One of 2 primary Japanese drug-pricing methodologies-the cost calculation method- refers extensively to the prediction of drug sales in establishing drug prices. Deviations from predicted...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1177/2168479019860123
更新日期：2019-07-16 00:00:00
abstract：:In the current pharmaceutical regulatory environment, patients continue to benefit from great advances in medical care. Sophisticated regulatory review systems have also evolved to ensure that safe and effective medicines are approved. However, these systems are not optimized in all countries. Gaps in individual regul...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1007/s43441-019-00055-9
更新日期：2020-03-01 00:00:00
abstract：BACKGROUND:Access and use of historical control data was identified as a top stakeholder concern across organizations according to results of a survey of needs and challenges related to nonclinical data conducted by the FDA/PhUSE Nonclinical Working Group in 2011. There is a perception there may be additional ways to c...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1177/2168479015600203
更新日期：2016-03-01 00:00:00
abstract：:In 2010 Congress established a regulatory pathway for the approval of biosimilar products in the United States. FDA has embarked on developing the implementation framework for this pathway which includes creating guidance to assist biosimilar manufacturers in the development of these products. However, to date, the gu...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1177/2168479013515249
更新日期：2014-05-01 00:00:00
abstract：BACKGROUND:The design and sample size of a phase III study for new medical technologies were historically determined within the framework of frequentist hypothesis testing. Recently, drug development using predictive biomarkers, which can predict efficacy based on the status of biomarkers, has attracted attention, and ...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1007/s43441-020-00119-1
更新日期：2020-09-01 00:00:00
abstract：:When does a single positive adequate and well-controlled study of a new drug meet the statutory requirement to demonstrate substantial evidence of effectiveness? The answer to this question, particularly with respect to new molecular entities, has been of considerable debate since 1962 when the requirement that new dr...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1007/s43441-019-00103-4
更新日期：2020-05-01 00:00:00
abstract：:A universal framework for the evaluation of the benefit-risk assessment of medicines during development by pharmaceutical companies and in the regulatory review by regulatory authorities is considered of value, as it would result in the systematic structured approach to support transparency in decision making. Several...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1177/2168479014547421
更新日期：2015-01-01 00:00:00
abstract：:Data quality is critical for clinical trials to obtain robust conclusions about drug safety and efficacy evaluation. Effective data quality evaluation has been one of the major obstacles to new drug approvals in China, which hinders innovation in drug discovery and development ultimately. To improve the data quality s...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1177/2168479018778528
更新日期：2019-03-01 00:00:00
abstract：:Lack of adherence to study protocol and missing data are often unavoidable in clinical trials, and both increase the need to differentiate between the ideal treatment effect if the medication is taken as directed and the treatment effect in presence of the actual adherence pattern. In this regard, estimands have becom...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1177/2168479014567317
更新日期：2015-07-01 00:00:00
abstract：:Quality and safety tests are required for regulatory approval of drugs and pharmaceuticals in the country to guarantee minimum safety standards, and most of these tests include animal usage. In the case of biological medicines, these safety and quality tests have to be performed on a batch-to-batch basis and require a...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1177/2168479015572371
更新日期：2015-09-01 00:00:00
abstract：:Biopharmaceutical medicines are complex molecules obtained from a living organism (plant or animal cells) and may contain components of a living organism using biotechnology. Biosimilars are closely similar to already approved biopharmaceutical products that could form a new generation of medicines that are available ...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章,评审
doi：10.1007/s43441-020-00112-8
更新日期：2020-09-01 00:00:00
abstract：:TransCelerate BioPharma Inc developed a methodology based on the notion that shifting monitoring processes from an excessive concentration on source data verification to comprehensive risk-driven monitoring will increase efficiencies and enhance patient safety and data integrity while maintaining adherence to good cli...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1177/2168479014546336
更新日期：2014-09-01 00:00:00
abstract：BACKGROUND:Substance abuse research can raise ethical concerns about the comprehension and decision-making capacities of participants with drug dependence. In this study, the competence and willingness to consent to research participation were examined among patients with heroin dependence. METHODS:Twenty patients wit...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1007/s43441-020-00127-1
更新日期：2020-09-01 00:00:00
abstract：:Adaptive designs are increasingly used in clinical trials. The Drug Information Association's Adaptive Design Scientific Working Group (ADSWG) works to foster collaboration among regulatory agencies, academia, and pharmaceutical and biotech companies to further the science of adaptive clinical development. The ADSWG S...
journal_title：Therapeutic innovation & regulatory science
pub_type： 杂志文章
doi：10.1177/2168479014522468
更新日期：2014-07-01 00:00:00
